TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32929841

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IM training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 35442196

Group type: EXPERIMENTAL
Intervention: CANreduce 2.0 intervention (self-guided web-based intervention, 6-week duration)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: CANreduce 2.0 intervention
Number of subjects: 367
Study: 33299019

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) cases confirmed by a rheumatologist based on 1987 ACR and/or 2010 ACR/EULAR criteria.
Number of subjects: 4916

Group type: COMPARATOR
Intervention: Population-based cross-sectional study design.
Number of subjects: 4916
Study: 35300670

Group type: EXPERIMENTAL
Intervention: Implementation of a culturally secure strategy for medical follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health information only control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nil-intervention control group
Number of subjects: 0
Study: 34710946

Group type: EXPERIMENTAL
Intervention: Sucrosomial iron (60 mg/day for one month)
Number of subjects: 1000
Study: 34958092

Group type: EXPERIMENTAL
Intervention: 3.5 g of MCH applied as SPLAT MCH (SPLAT3.5)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 3.5 g of Acer kairomone blend (AKB)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 3.5 g of acetophenone + green leaf volatiles (PLUS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 7 g of MCH applied as SPLAT MCH (SPLAT7)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 7 g of Acer kairomone blend (AKB)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 7 g of acetophenone + green leaf volatiles (PLUS)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Baited control (bait only)
Number of subjects: 91
Study: 32978193

Group type: EXPERIMENTAL
Intervention: Cadaveric simulation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 'on-the-job' training
Number of subjects: 0
Study: 35626843

Group type: EXPERIMENTAL
Intervention: Culturally adapted dental visual aids
Number of subjects: 64

Group type: COMPARATOR
Intervention: Regular dental visual aids
Number of subjects: 64
Study: 32118826

Group type: EXPERIMENTAL
Intervention: Hemorrhage + CRM (n = 22)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hemorrhage (n = 31)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (n = 24)
Number of subjects: 77
Study: 32354661

Group type: EXPERIMENTAL
Intervention: Continuum beliefs induced with videos supporting a continuum viewpoint of schizophrenia
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Categorial beliefs induced with videos supporting a categorial viewpoint of schizophrenia
Number of subjects: 565

Group type: COMPARATOR
Intervention: Neutral video (control group)
Number of subjects: 565
Study: 34551129

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 100
Study: 33148601

Group type: EXPERIMENTAL
Intervention: Prospective monitoring of outcomes using control charts with regular feedback on indicators (intervention group)
Number of subjects: 155362

Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 155362
Study: 36093579

Group type: EXPERIMENTAL
Intervention: Short-headed toothbrush (Curaprox CS 5460)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional toothbrush (ultrasoft)
Number of subjects: 20
Study: 33184151

Group type: EXPERIMENTAL
Intervention: Habits-GDM smartphone application coaching program
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 340
Study: 32022286

Group type: EXPERIMENTAL
Intervention: Glepaglutide 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glepaglutide
Number of subjects: 18
Study: 36307156

Group type: EXPERIMENTAL
Intervention: Recruitment manoeuvres (RMs) with sequential high-flow nasal oxygen therapy (HFNO) after extubation
Number of subjects: 654

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 654
Study: 34159536

Group type: EXPERIMENTAL
Intervention: BCI‐FES group
Number of subjects: 32

Group type: COMPARATOR
Intervention: NMES group
Number of subjects: 32
Study: 32156696

Group type: EXPERIMENTAL
Intervention: Primary ciliary dyskinesia (PCD)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Cystic fibrosis (CF)
Number of subjects: 333
Study: 34465344

Group type: COMPARATOR
Intervention: Sanitary pad distribution
Number of subjects: 3489

Group type: COMPARATOR
Intervention: Reproductive health education
Number of subjects: 3489

Group type: COMPARATOR
Intervention: Both sanitary pad distribution and reproductive health education
Number of subjects: 3489
Study: 32493335

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study: 35721715

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram combining Rad-score and clinical risk factors (radiologists' interpretation)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Radiomics models (K-nearest neighbor, logistic regression, decision tree, linear-SVM, gaussian-SVM, polynomial-SVM)
Number of subjects: 153
Study: 34959887

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Other FoPLs
Number of subjects: 1059

Group type: COMPARATOR
Intervention: No label condition
Number of subjects: 1059
Study: 34838889

Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling every 2 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 58
Study: 33297608

Group type: EXPERIMENTAL
Intervention: PKP concurrently combined with ZOL
Number of subjects: 600

Group type: COMPARATOR
Intervention: PKP alone
Number of subjects: 600

Group type: COMPARATOR
Intervention: PKP combined with ZOL 1 month later
Number of subjects: 600
Study: 35158230

Group type: EXPERIMENTAL
Intervention: 50 μg lysergic acid diethylamide (LSD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 24
Study: 35428571

Group type: EXPERIMENTAL
Intervention: Patient-friendly audiovisual (AV) system
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard system (control)
Number of subjects: 61
Study: 32443412

Group type: EXPERIMENTAL
Intervention: Fortified complementary food supplements (CFSs)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Two of the four CFSs
Number of subjects: 752

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 752
Study: 35622456

Group type: EXPERIMENTAL
Intervention: E2027 (doses ranging from 5 to 1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2027 (doses planned for phase 2 study)
Number of subjects: 0
Study: 33229934

Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes as a cessation strategy (among participants attempting to quit, N = 137)
Number of subjects: 179
Study: 34773634

Group type: EXPERIMENTAL
Intervention: Dapoxetine/Tadalafil (DT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paroxetine/Tadalafil (PT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dapoxetine (Da)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paroxetine (Pa)
Number of subjects: 120
Study: 32590151

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 165
Study: 34245744

Group type: EXPERIMENTAL
Intervention: Antiviral drug therapy
Number of subjects: 50
Study: 36444953

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen before removal of drainage tubes and a second dose at 8 p.m. on the same day.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Routine treatment without acetaminophen (control group).
Number of subjects: 183
Study: 35852641

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (nab-PTX)
Number of subjects: 38
Study: 33046345

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard Dressings
Number of subjects: 119
Study: 35583268

Group type: EXPERIMENTAL
Intervention: iADAPT application
Number of subjects: 31

Group type: COMPARATOR
Intervention: Workbook
Number of subjects: 31
Study: 33594991

Group type: EXPERIMENTAL
Intervention: Prospective expectancy‐only condition
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Retrospective expectancy‐only condition
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined expectancy condition
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study: 35193648

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 130 solution (Volulyte 6%, Fresenius Kabi, Germany)
Number of subjects: 2280

Group type: COMPARATOR
Intervention: Crystalloid solution (Ionolyte, Fresenius Kabi, Germany)
Number of subjects: 2280
Study: 34167639

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 18846

Group type: COMPARATOR
Intervention: Nonuse of statins
Number of subjects: 18846
Study: 32173766

Group type: EXPERIMENTAL
Intervention: M-VO2peak (38 min of cycling at 70% VO2peak)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: M-IAT (38 min of cycling at 97% of individual anaerobic lactate threshold)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: M-VT (38 min of cycling at 67% between ventilatory thresholds 1 and 2)
Number of subjects: 40
Study: 35979057

Group type: EXPERIMENTAL
Intervention: Propofol intravenous anesthesia combined with press-needle therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Propofol intravenous anesthesia
Number of subjects: 128
Study: 33878522

Group type: EXPERIMENTAL
Intervention: Active Audiovisual Stimulation (AVS) for 30 minutes at bedtime (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control for 30 minutes at bedtime (n = 15)
Number of subjects: 30
Study: 33259540

Group type: EXPERIMENTAL
Intervention: Core warming via an esophageal heat exchanger
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 20
Study: 36329189

Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining (BCR) prostheses
Number of subjects: 77

Group type: COMPARATOR
Intervention: Posterior-stabilized (PS) prostheses
Number of subjects: 77
Study: 34297713

Group type: EXPERIMENTAL
Intervention: Icon array
Number of subjects: 407

Group type: COMPARATOR
Intervention: Bar graph
Number of subjects: 407
Study: 35762946

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBTi)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Audiology-Based Care (ABC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sleep Support Group (SSG)
Number of subjects: 102
Study: 33622954

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 46

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 46
Study: 33152700

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD‐MTX; 3‐8 g/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HD‐MTX-based therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel regimens (ibrutinib, lenalidomide + rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-brain radiation therapy
Number of subjects: 0
Study: 35624433

Group type: EXPERIMENTAL
Intervention: New prognostic model for overall survival (OS) based on IPI, β2-microglobulin, platelet count, and red blood cell distribution width.
Number of subjects: 998
Study: 34313842

Group type: EXPERIMENTAL
Intervention: Gay-specific Trier Social Stress Test (TSST)
Number of subjects: 33

Group type: COMPARATOR
Intervention: General Trier Social Stress Test (TSST)
Number of subjects: 33
Study: 32358381

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 0
Study: 35502662

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 5091

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 5091
Study: 33481780

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) for soil-transmitted helminths (STH)
Number of subjects: 0
Study: 35258400

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Screening Control (SC)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Non-Screening Control (NSC)
Number of subjects: 486
Study: 33724256

Group type: EXPERIMENTAL
Intervention: Celecoxib augmentation (n = 18)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment as usual (n = 9)
Number of subjects: 27
Study: 33371159

Group type: EXPERIMENTAL
Intervention: Shi-style spine balance manipulation combined with Daoyin therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lumbar mechanical traction
Number of subjects: 72
Study: 35758335

Group type: EXPERIMENTAL
Intervention: Pair-switching rerandomization (PSRR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical rerandomization
Number of subjects: 0
Study: 34143559

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medical air (control)
Number of subjects: 12
Study: 32297875

Group type: EXPERIMENTAL
Intervention: Peer-delivered, internet-based messaging intervention (educational and motivational messages) over 12 weeks.
Number of subjects: 244
Study: 33834521

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg plus TCS
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg plus TCS
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo plus TCS
Number of subjects: 329
Study: 33560442

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with rituximab
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard chemotherapy without rituximab
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 30-Gy whole-brain radiotherapy (WBRT)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Changes in white matter abnormalities and cerebral atrophy
Number of subjects: 199
Study: 36377367

Group type: EXPERIMENTAL
Intervention: NEW‐R intervention
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 113
Study: 34436611

Group type: EXPERIMENTAL
Intervention: COVID‐19 mitigation measures
Number of subjects: 764
Study: 35414092

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) consisting of eight modules focusing on psychoeducation, cognitive restructuring, pacing, and emotion regulation, with weekly written feedback from a trained therapist.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 120
Study: 34488326

Group type: EXPERIMENTAL
Intervention: Pethidine (100 mg as intravenous infusion)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (routine cares)
Number of subjects: 116
Study: 32881912

Group type: EXPERIMENTAL
Intervention: Sitagliptin (DPP4i) at 100mg daily for 28 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 35655231

Group type: EXPERIMENTAL
Intervention: Home-based virtual reality training (MIND-VR and The Secret Garden) consisting of three sessions in one week using Oculus Quest 2.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with no training.
Number of subjects: 60
Study: 32914866

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 444

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 444
Study: 34812982

Group type: COMPARATOR
Intervention: Cytoreductive surgery (CRS) alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) with or without HIPEC
Number of subjects: 71
Study: 33145862

Group type: EXPERIMENTAL
Intervention: Paracetamol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose NSAID (piroxicam) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol and high-dose NSAID combination
Number of subjects: 0
Study: 35616410

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at sensitization points
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at CV4
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (corn oil gavage)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Model group (BPA gavage)
Number of subjects: 26
Study: 34189832

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33322280

Group type: EXPERIMENTAL
Intervention: 8% maltodextrin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (20 g/day) and 8% maltodextrin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypoxia and placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia and carbohydrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypoxia and glutamine supplementation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 9
Study: 34857545

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor dapagliflozin (5 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32347767

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) post-dose 2
Number of subjects: 0
Study: 33915962

Group type: COMPARATOR
Intervention: Reishi Mushroom (lower-dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reishi Mushroom (higher-dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Stinging Nettle (lower-dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Stinging Nettle (higher-dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Epimedium (lower-dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Epimedium (higher-dose)
Number of subjects: 29
Study: 34644471

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 international units daily)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 290
Study: 32807447

Group type: EXPERIMENTAL
Intervention: Pedaling exercises for 10 minutes at a load of 5 Nm and rotation speed of 40 rpm
Number of subjects: 21

Group type: COMPARATOR
Intervention: Walking group (control) for 10 minutes
Number of subjects: 21
Study: 36334895

Group type: EXPERIMENTAL
Intervention: Feedback on radiation protection (RP) performance after each case
Number of subjects: 24

Group type: COMPARATOR
Intervention: No feedback on radiation protection (RP) performance after each case
Number of subjects: 24
Study: 34756606

Group type: EXPERIMENTAL
Intervention: Anodized titanium abutment collars
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unanodized titanium abutment collars (control)
Number of subjects: 30
Study: 34639396

Group type: EXPERIMENTAL
Intervention: Drum playing intervention with rhythmic cueing (DPRC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 35833454

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day, titrated every 3-4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 11
Study: 33905493

Group type: EXPERIMENTAL
Intervention: 64 mg guanabenz
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 32 mg guanabenz
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 16 mg guanabenz
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: COMPARATOR
Intervention: Historical cohort
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All guanabenz arms
Number of subjects: 200
Study: 35488976

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Parent Training (BPT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Active control (psychoeducation/supportive therapy)
Number of subjects: 38
Study: 34592135

Group type: EXPERIMENTAL
Intervention: Costochondral graft (CCG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Gap arthroplasty (GA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both CCG and GA
Number of subjects: 56
Study: 35256635

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasmajet (CAP-jet)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Best practice wound dressings (BP)
Number of subjects: 78
Study: 32169808

Group type: EXPERIMENTAL
Intervention: DCs vaccine (group III)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trans-arterial chemoembolization (TACE) and DCs as adjuvant therapy (group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supportive treatment (group IV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: TACE only (group II)
Number of subjects: 20
Study: 33618592

Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 37
Study: 35141803

Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 150

Group type: COMPARATOR
Intervention: Neutral head position
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Head extension position
Number of subjects: 150
Study: 33978070

Group type: EXPERIMENTAL
Intervention: Integrated approach including balloon uterine stent placement, artificial cycle, intrauterine perfusion of Danshen injection, and oral Chinese medicine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group with balloon uterine stent placement, artificial cycle, hyaluronic acid sodium, and intrauterine device (IUD)
Number of subjects: 70
Study: 32084530

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg or 8 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 82